Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

BALA CYNWYD, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

Oak Street Health (NYSE – OSH)

Under the terms of the deal, Oak Street Health will be acquired by CVS Health® (“CVS”) (NYSE - CVS). Oak Street Health stockholders will receive $39.00 per share in an all-cash transaction, representing an enterprise value of approximately $10.6 billion. The investigation concerns whether the Oak Street Health Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether CVS is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/oak-street-health-nyse-osh/.

Seagen Inc. (Nasdaq - SGEN)

Under the terms of the agreement, Seagen will be acquired by Pfizer Inc. (NYSE - PFE). Pfizer will pay $229.00 in cash for each share of Seagen common stock in a deal with an enterprise value of approximately $43 billion. The investigation concerns whether the Seagen Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Pfizer is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/seagen-inc-nasdaq-sgen/.

Provention Bio Inc. (Nasdaq - PRVB)

Under the terms of the agreement, Provention will be acquired by Sanofi (Nasdaq - SNY). Sanofi will pay $25.00 in cash for each share of Provention common stock in a deal valued at approximately $2.9 billion. The investigation concerns whether the Provention Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Sanofi is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/provention-bio-inc-nasdaq-prvb/.

Kimball International, Inc. (Nasdaq – KBAL)

Under the terms of the Merger Agreement, Kimball will be acquired by HNI Corporation (NYSE - HNI). Kimball shareholders will receive $9.00 in cash and 0.1301 shares of HNI common stock for each share of Kimball common stock they own. As a result of the transaction, Kimball shareholders will own approximately 10% of the combined company. The investigation concerns whether the Kimball Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Kimball shareholders in the combined company and whether HNI is paying too little for the Company.

Additional information can be found at https://www.brodskysmith.com/cases/kimball-international-inc-nasdaq-kbal/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.